Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Andre

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Journal of Gastrointestinal Cancer|March 11, 2014
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasisMatthieu Faron, Mircea Chirica, Hadrien Tranchard, et al.
Anticancer Research|July 9, 2011
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancerOlivier Bouche, Frederique Maindrault-Goebel, Michel Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2024
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patientsOfer Margalit, Amos Stemmer, William J Chapin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancerRichard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Journal of the National Cancer Institute|April 16, 2020
Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal CancerKaysia Ludford, Romain Cohen, Magali Svrcek, et al.
Future Oncology (London, England)|December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancerJohn H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Annals of Surgical Oncology|July 7, 2018
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE StudyBrice Malgras, Etienne Gayat, Olivier Aoun, et al.
Presse Medicale (Paris, France : 1983)|October 24, 2007
[PET and digestive cancers]Jean-Noël Talbot, Françoise Montravers, Fabrice Gutman, et al.
Bulletin Du Cancer|January 9, 2021
[What should we remember from 2020?]Jacques-Olivier Bay, Thierry Andre, Carole Bouleuc, et al.
BMC Cancer|July 9, 2016
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programAntoine Adenis, Christelle de la Fouchardiere, Bernard Paule, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Journal of Gastrointestinal Cancer|March 11, 2014
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasisMatthieu Faron, Mircea Chirica, Hadrien Tranchard, et al.
Anticancer Research|July 9, 2011
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancerOlivier Bouche, Frederique Maindrault-Goebel, Michel Ducreux, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2024
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patientsOfer Margalit, Amos Stemmer, William J Chapin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancerRichard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Journal of the National Cancer Institute|April 16, 2020
Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal CancerKaysia Ludford, Romain Cohen, Magali Svrcek, et al.
Future Oncology (London, England)|December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancerJohn H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Annals of Surgical Oncology|July 7, 2018
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE StudyBrice Malgras, Etienne Gayat, Olivier Aoun, et al.
Presse Medicale (Paris, France : 1983)|October 24, 2007
[PET and digestive cancers]Jean-Noël Talbot, Françoise Montravers, Fabrice Gutman, et al.
Bulletin Du Cancer|January 9, 2021
[What should we remember from 2020?]Jacques-Olivier Bay, Thierry Andre, Carole Bouleuc, et al.
BMC Cancer|July 9, 2016
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use programAntoine Adenis, Christelle de la Fouchardiere, Bernard Paule, et al.
Pageof 6